BMS-986470

DRUG2 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Bristol-Myers Squibb

Conditions

Anemia, Sickle CellHealthy VolunteersSickle Cell Disease

Phase 1

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

RecruitingNCT06481306

Bristol-Myers SquibbAnemia, Sickle Cell, Healthy Volunteers

Start: 2024-07-17End: 2027-11-16Target: 224Updated: 2026-08-18

A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants with Sickle Cell Disease to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability, pH and Food Effect, and Preliminary Efficacy of BMS-986470

RecruitingCTIS2023-510283-12-00

Bristol-Myers Squibb Services Unlimited CompanySickle Cell Disease

Start: 2025-06-12Target: 6Updated: 2025-09-05

Related Papers

Development of a ZBTB7A and Wiz Dual Degrading, HbF-Activating CELMoD™ for the Treatment of Sickle Cell Disease

Blood2024-11-053 citations